<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="obesemini/PMC6333581/results/search/drugs/results.xml">
  <result pre="behavioral intervention. Orlistat, metformin, glucagon-like peptide 1 (GLP-1) agonists, and" exact="topiramate" post="are available in adult obesity, and there have been"/>
  <result pre="[ 141 147]. Data on the single drug use of" exact="orlistat" post="without behavioral therapy are not available. In case of"/>
  <result pre="it difficult to prescribe to school-aged children. In some reports," exact="orlistat" post="interferes with the absorption of fat-soluble vitamins, such as"/>
  <result pre="pediatric use. Younger patients are recommended to take multivitamins because" exact="orlistat" post="can hinder the absorption of fat-soluble vitamins, such as"/>
  <result pre="BMI of 26 to 40 kg/m 2 [ 153]. Although" exact="metformin" post="can be used by type 2 DM children, it"/>
  <result pre="months of use of metformin. A previous study reported that" exact="metformin" post="has some effects in children with insulin resistance ["/>
  <result pre="some effects in children with insulin resistance [ 158]. Although" exact="metformin" post="could be used in the short term, along with"/>
  <result pre="after food consumption, inducing satiety by delaying gastric emptying and" exact="glucagon" post="secretion. It also controls appetite and satiety in the"/>
  <result pre="disease [ 152]. Therefore, it is not recommended to use" exact="liraglutide" post="for childhood obesity treatment. 4) Topiramate Topiramate is a"/>
  <result pre="aged 12 years and older). The weight loss effect of" exact="zonisamide" post="(voltage-dependent sodium channels and T-type calcium blocker) was observed"/>
  <result pre="[ 141 152 153]. Despite the weight control effect of" exact="topiramate" post="and zonisamide, the findings of epilepsy studies cannot be"/>
  <result pre="of phentermine-topiramate in pediatric obesity [ 152]. The effect of" exact="zonisamide" post="in pediatric obesity was reported in case reports of"/>
  <result pre="and memory deficit, somnolence, and diarrhea have been associated with" exact="topiramate" post="and zonisamide [ 143 144 146]. Serious side effects"/>
  <result pre="deficit, somnolence, and diarrhea have been associated with topiramate and" exact="zonisamide" post="[ 143 144 146]. Serious side effects were reported"/>
  <result pre="stone [ 152]. Therefore, it is not recommended to use" exact="topiramate" post="for the treatment of childhood obesity. 7-2. We recommend"/>
  <result pre="Rudser KD Gross A Kelly AS Fox CK Effect of" exact="phentermine" post="on weight reduction in a pediatric weight management clinic"/>
  <result pre="Gross AC Sunni M et al. Meal replacements followed by" exact="topiramate" post="for the treatment of adolescent severe obesity: a pilot"/>
  <result pre="Hampl S Jensen C Boldrin M Hauptman J Effect of" exact="orlistat" post="on weight and body composition in obese adolescents: a"/>
  <result pre="McDuffie JR Kozlosky M Sebring NG et al. Effects of" exact="metformin" post="on body weight and body composition in obese insulin-resistant"/>
  <result pre="J Qualls C et al. Randomized, double-blind, placebo-controlled trial of" exact="orlistat" post="for weight loss in adolescents Endocr Pract 2006 12"/>
  <result pre="x xi 22093860 155 Atabek ME Pirgon O Use of" exact="metformin" post="in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind,"/>
  <result pre="Krakoff J Calis KA Brady SM et al. Effects of" exact="metformin" post="on energy intake and satiety in obese children Diabetes"/>
  <result pre="placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of" exact="liraglutide" post="in adolescents aged 12â€“17 years J Pediatr 2017 181"/>
 </snippets>
</snippetsTree>
